A local bio-technology company has found a coronavirus vaccine candidate, and the first in-human trial is expected to begin in May. Novavax, which is located in Gaithersburg, develops next-generation vaccines for serious infectious diseases. Officials say they will be using NVX-CoV2373, which is described as a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. “Our scientists […]
NVX-CoV2373
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia